OncoMed Pharma (OMED) Misses Q2 EPS by 10c

OncoMed Pharma (NASDAQ: OMED) reported Q2 EPS of ($0.91), $0.10 worse than the analyst estimate of ($0.81). Revenue for the quarter came in at $6.7 million versus the consensus estimate of $8.09 million.

For earnings history and earnings-related data on OncoMed Pharma (OMED) click here.

You May Also Be Interested In

• Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
• Tractor Supply (TSCO) Tops Q1 EPS by 12c ; Offers Guidance
• United Bankshares (UBSI) Misses Q1 EPS by 1c